Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: A real-life strategy

Liver International

Volumn 37, Issue 5, 2017, Pages 678-683

  Donato, Maria Francesca ^a   Morelli, Cristina ^b   Romagnoli, Renato ^c   Invernizzi, Federica ^a   Mazzarelli, Chiara ^d   Iemmolo, Rosa Maria ^e   Montalbano, Marzia ^f   Lenci, Ilaria ^g   Bhoori, Sherrie ^h   Pieri, Giulia ⁱ   Berardi, Sonia ^b,k   Caraceni, Paolo ^b   Martini, Silvia ^j   Angeli, Paolo ^k   Belli, Luca Saverio ^k   Bernabucci, Veronica ^k   Malinverno, Federica ^k   Monico, Sara ^k   Ottobrelli, Antonio ^k   Romano, Antonietta ^k   Strona, Silvia ^k   Tamè, Maria Rosa ^k   Visco Comandini, Ubaldo ^k   Cavenago, Margherita ^k   De Carlis, Luciano ^k   Di Benedetto, Fabrizio ^k   Dondossola, Daniele ^k   Ettorre, Giuseppe Maria ^k   Mazzaferro, Vincenzo ^k   Montin, Umberto ^k   Pinna, Antonio Daniele ^k   Rossi, Giorgio ^k   Salizzoni, Mauro ^k   Tisone, Giuseppe ^k   more..

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^g UNIVERSITY OF ROME TOR VERGATA   (Italy)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^k AOU Città della Salute e della Scienza di Torino ^*

more..

Author keywords

Hepatitis C; Hepatocellular carcinoma; Liver transplant; Sofosbuvir therapy; Virological response

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORINE; DACLATASVIR; ERYTHROPOIETIN; MYCOPHENOLATE MOFETIL; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; VIRUS RNA; ANTIVIRUS AGENT;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TRANSFUSION; DECOMPENSATED LIVER CIRRHOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MIDDLE AGED; MONOTHERAPY; MULTIPLE ORGAN FAILURE; NAUSEA; NEUTROPENIA; PAROXYSMAL ATRIAL FIBRILLATION; RECURRENT INFECTION; RETRANSPLANTATION; SEPSIS; COMBINATION DRUG THERAPY; FEMALE; GENETICS; HEPACIVIRUS; ITALY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RECURRENT DISEASE; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; ITALY; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE;

EID: 85007389973     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13322     Document Type: Article

References (27)

1. Saxena V, Terrault NA. Current management of hepatitis C virus: regimens for peri-liver transplant patients. Clin Liver Dis. 2015;19:669–688.
2. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology. 2013;58:428–438.
3. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146:1176–1192.
4. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2016. doi: 10.1016/j.jhep.2016.09.001.2017;66:153–194.
5. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889–896.
6. Burra P, Germani G, Adam R, et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol. 2013;58:287–296.
7. Howell J, Angus P, Gow P. Hepatitis C recurrence: the Achilles heel of liver transplantation. Transpl Infect Dis. 2014;16:1–16.
8. Degasperi E, Aghemo A. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepat Med. 2014;6:25–33.
9. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015;148:100–107.
10. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148:108–117.
11. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61:1485–1494.
12. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649–659.
13. Manns M, Samuel D, Gane EJ, et al. Ledipasvir/sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicenter, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685–697.
14. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 study. Hepatology. 2016;63:1493–1505.
15. Aghemo A, Donato MF. Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better. Gastroenterology. 2015;148:13–16.
16. Donato MF, Monico S, Malinverno F, et al. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? Liver Int. 2015;35:1–4.
17. Everson GT. PRO view: treat to prevent recurrence of HCV. Liver Int. 2015;35:5–6.
18. Martini S, Donato MF, Mazzarelli C, et al. Compassionate use of sofosbuvir (ITACOPS) in patients with HCV-related cirrhosis waitlisted for liver transplantation: virological and clinical outcomes from a National real-life experience. Hepatology. 2015;62:1395A, LB26.
19. Everson GT, Terrault NA, Lok AS, et al. A randomized controlled trial of pre-transplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2013;57:1752–1762.
20. Gurusamy KS, Tsochatzis E, Toon CD, Davidson BR, Burroughs AK. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev. 2013;12:CD006803.
21. Fortune BE, Martinez-Camacho A, Kreidler S, Gralla J, Everson GT. Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation. Transpl Int. 2015;28:980–989.
22. Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl. 2004;10:349–355.
23. Viganò M, Colombo M. Extrahepatic manifestations of hepatitis C virus. Gastroenterol Clin North Am. 2015;44:775–791.
24. Angelico M, Cillo U, Fagiuoli S, et al. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor–recipient matching. Dig Liver Dis. 2011;43:155–164.
25. Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224–1231.
26. Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–2628.
27. Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807–816.